Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T™ in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS) (June 26, 2019)
Moffitt Cancer Center Partners with TuHURA Biopharma Inc. to Develop a New Generation of Targeted Immunotherapies (May 29, 2019)
Lixte Biotechnology Announces a Clinical Trial Agreement with Moffitt Cancer Center to Initiate Phase 1b/2 Trial Evaluating the Safety and Efficacy of LB-100 in Treatment of Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome (August 21, 2018)
Moffitt Cancer Center Announces Licensing Agreement to Develop New Therapeutic Cancer Vaccine (July 10, 2018)
Licensing, partnerships drive Moffitt financial gains (Tampa Bay Business Journal May 18, 2018)
GLG Pharma, a Moffitt Start-up, Announces a Joint Strategic Partnership with Skyline Medical and Helomics (November 28, 2017)
Moffitt Start-up Wins Biopitch Competition at BioFlorida Conference (November 1, 2017)
Moffitt Cancer Center Founder H. Lee Moffitt Receives BioFlorida Lifetime Achievement Award (October 12, 2017)
Hearst invests in Moffitt Cancer Center subsidiary M2Gen (September 20, 2017)
Moffitt Cancer Center & Cvergenx Partner to Personalize Radiation Therapy (August 9, 2017)
Bay News 9 - An in-depth interview with Jarett Rieger, Business of Biotech Conference Chairman (February 21, 2017)
Lion Biotechnologies Announces New Sponsored Research and Clinical Grant Agreements with H. Lee Moffitt Cancer Center and Research Institute (December 20, 2016)
Innovation Office Connects Moffitt and Signal Genetics for Myeloma Research
Incyte and Moffitt Cancer Center Establish Multi-Year Oncology Research Alliance (June 1, 2016)
Moffitt Cancer Center Showcases Startups at 10th Annual Business of Biotech Conference (February 18, 2016)
Top research taking place in Tampa leads to national recognition for innovation, patents (83 Degrees, December 15, 2015)
Dr. Letson of Moffitt Cancer Center named Fellow of the National Academy of Inventors (December 16, 2015)
Moffitt Cancer Center and Ignyta, Inc. Enter into Cancer Research Collaboration for RXDX-106 (November 20, 2015)
Moffitt Cancer Center Grants Aptose Exclusive Global Rights to Highly Potent Multi-Targeting Epigenetic Inhibitors (November 11, 2015)
HealthMyne, Inc. and Moffitt Cancer Center Sign Imaging Analytics Technology Agreement (Business Wire, October 6, 2015)
Bristol-Myers Squibb and Moffitt Cancer Center Enter into a Collaboration Agreement (Business Wire, September 25, 2015)
Signal Genetics and Moffitt Cancer Center Enter Into Sponsored Research Agreement in Multiple Myeloma (September 8, 2015)
Rosetta Genomics Announces Selection of First Pilot Project Grant under Strategic Alliance with Moffitt Cancer Center
(May 26, 2015)
Prescient Therapeutics Acquires Exclusive Worldwide License for Cancer Biomarker p27 (Prescient Therapeutics, February 9, 2015)
Celgene Wins Rights To Moffitt's Investigational MDS Therapy (BioProcess Online, November 20, 2014)
Moffitt signs deal for experimental treatment (Business Observer, November 18, 2014)
Moffitt, Celgene pair on treatment for cancer that struck GMA host Robin Roberts (Tampa Bay Business Journal, November 17, 2014)
Moffitt Cancer Center Announces Development of Experimental Treatment for Myelodysplastic Syndromes, Autoimmune Diseases (Business Wire, November 17, 2014)
HealthMyne Put the Band Back Together to Unite Medical Images & Data (XCompany November 11, 2014)
Forma Therapeutics and Moffitt Cancer Center Establish Multiyear Epigenetics Alliance (Business Wire, September 23, 2014)
MediFuture 2024 Jarrett Rieger Interview (September 18, 2014)
Hillsborough committee approves $200,000 in innovation grants (The Tampa Tribune, September 11, 2014)
Rosetta Genomics and Moffitt Cancer Center Enter into Strategic Alliance to Develop microRNA-based Cancer Diagnostics (September 2, 2014)
Virax Holdings Ltd enters in to option agreement to acquire Worldwide License from Moffitt Cancer Center (Reuters, Sunday, 4 May 2014 )

Media/News